Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own

For Campus Prearrival Information <click here>
For a PDF of the 2015 Program Materials <click here>
For ALL Abstracts [1-220] in sequential order <click here>
For ALL Authors of the Lecture and Poster Presentations <click here>


View analytic
Thursday, August 27 • 2:40pm - 3:20pm
[0194] Synthesis and Up-Scaling of Finerenone, a Novel Potent and Selective Oral Non-Steroidal Mineralo-Corticoid Receptor (MR) Antagonist

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

Finerenone (BAY 94-8862) is a novel potent and selective oral non-steroidal mineralo-corticoid receptor (MR) antagonist blocking deleterious effects of aldosterone. Increased activation of the MR leads to pathological changes in the heart and kidneys, which can be prevented by effective MR antagonism. Finerenone has demonstrated a promising efficacy and safety profile in preclinical studies as well as in Phase IIa. The MR antagonist is currently in clinical Phase IIb development for the treatment of worsening chronic heart failure and diabetic nephropathy and is expected to enter clinical Phase III end of 2015. Synthesis and up-scaling of the novel optical active Dihydropyridine derivative to commercial scale, as well as challenges during process development will be discussed. Application of SMB technique for separation of enantiomers on large scale will be demonstrated. Additionally, the synthesis and characterization of metabolites will be presented.


Invited Lecturers
avatar for Johannes Platzek

Johannes Platzek

Bayer Healthcare


Thursday August 27, 2015 2:40pm - 3:20pm
MCC Theater